204 related articles for article (PubMed ID: 25424788)
21. Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation.
Van Nuffel AM; Corthals J; Neyns B; Heirman C; Thielemans K; Bonehill A
Methods Mol Biol; 2010; 629():405-52. PubMed ID: 20387165
[TBL] [Abstract][Full Text] [Related]
22. Guiding the "misguided" - functional conditioning of dendritic cells for the DC-based immunotherapy against tumours.
Huang FP; Chen YX; To CK
Eur J Immunol; 2011 Jan; 41(1):18-25. PubMed ID: 21182072
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cell-based cancer immunotherapy: the stagnant approach and a theoretical solution.
Subbotin VM
Drug Discov Today; 2014 Jul; 19(7):834-7. PubMed ID: 24603211
[TBL] [Abstract][Full Text] [Related]
24. [Reduction of immunosuppression and shift to Th1 response by tumor-DC (dendritic cells) fusion vaccine].
Iinuma H; Okinaga K; Fukushima R; Inaba T; Iwasaki K; Arai T; Tamura J; Kumagai H
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1640-2. PubMed ID: 15553669
[TBL] [Abstract][Full Text] [Related]
25. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy.
Schreibelt G; Tel J; Sliepen KH; Benitez-Ribas D; Figdor CG; Adema GJ; de Vries IJ
Cancer Immunol Immunother; 2010 Oct; 59(10):1573-82. PubMed ID: 20204387
[TBL] [Abstract][Full Text] [Related]
26. Dendritic cell-based cancer therapy.
Conrad C; Nestle FO
Curr Opin Mol Ther; 2003 Aug; 5(4):405-12. PubMed ID: 14513684
[TBL] [Abstract][Full Text] [Related]
27. Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo.
Vogt A; Sievers E; Lukacs-Kornek V; Decker G; Raskopf E; Meumann N; Büning H; Sauerbruch T; Strassburg CP; Schmidt-Wolf IG; Gonzalez-Carmona MA
Liver Int; 2014 Mar; 34(3):447-61. PubMed ID: 23998316
[TBL] [Abstract][Full Text] [Related]
28. Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.
Coosemans A; Vanderstraeten A; Tuyaerts S; Verschuere T; Moerman P; Berneman Z; Vergote I; Amant F; Van Gool SW
Anticancer Res; 2013 Sep; 33(9):3855-9. PubMed ID: 24023319
[TBL] [Abstract][Full Text] [Related]
29. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
30. Dendritic-tumor fusion cells in cancer immunotherapy.
Takakura K; Kajihara M; Ito Z; Ohkusa T; Gong J; Koido S
Discov Med; 2015 Mar; 19(104):169-74. PubMed ID: 25828520
[TBL] [Abstract][Full Text] [Related]
31. Current issues in dendritic cell cancer immunotherapy.
López JA; Hart DN
Curr Opin Mol Ther; 2002 Feb; 4(1):54-63. PubMed ID: 11885565
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer.
Wang S; Wang Z
Int Immunopharmacol; 2015 Sep; 28(1):22-8. PubMed ID: 26013109
[TBL] [Abstract][Full Text] [Related]
33. Current status and perspectives of immune-based therapies for hepatocellular carcinoma.
Aerts M; Benteyn D; Van Vlierberghe H; Thielemans K; Reynaert H
World J Gastroenterol; 2016 Jan; 22(1):253-61. PubMed ID: 26755874
[TBL] [Abstract][Full Text] [Related]
34. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
Han Y; Chen Z; Yang Y; Jiang Z; Gu Y; Liu Y; Lin C; Pan Z; Yu Y; Jiang M; Zhou W; Cao X
Hepatology; 2014 Feb; 59(2):567-79. PubMed ID: 23960017
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cell biology and cancer therapy.
Whiteside TL; Odoux C
Cancer Immunol Immunother; 2004 Mar; 53(3):240-8. PubMed ID: 14685779
[TBL] [Abstract][Full Text] [Related]
36. Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.
Bol KF; Schreibelt G; Gerritsen WR; de Vries IJ; Figdor CG
Clin Cancer Res; 2016 Apr; 22(8):1897-906. PubMed ID: 27084743
[TBL] [Abstract][Full Text] [Related]
37. Combined E7-dendritic cell-based immunotherapy and human sodium/iodide symporter radioiodine gene therapy with monitoring of antitumor effects by bioluminescent imaging in a mouse model of uterine cervical cancer.
Jeon YH; Lee HW; Lee YL; Kim JE; Hwang MH; Jeong SY; Lee SW; Ahn BC; Ha JH; Lee J
Cancer Biother Radiopharm; 2011 Dec; 26(6):671-9. PubMed ID: 22091632
[TBL] [Abstract][Full Text] [Related]
38. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cells and cancer immunotherapy.
Radford KJ; Tullett KM; Lahoud MH
Curr Opin Immunol; 2014 Apr; 27():26-32. PubMed ID: 24513968
[TBL] [Abstract][Full Text] [Related]
40. Dendritic cell immunotherapy in ovarian cancer.
Stiff PJ; Czerlanis C; Drakes ML
Expert Rev Anticancer Ther; 2013 Jan; 13(1):43-53. PubMed ID: 23259426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
